IQGAP1 restrains T‐cell cosignaling mediated by OX40
Open Access
- 25 November 2019
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 34 (1) , 540-554
Abstract
A costimulatory signal from the tumor necrosis factor receptor (TNFR) family molecule OX40 (CD134), which is induced on activated T cells, is important for T‐cell immunity. Aberrant OX40 cosignaling has been implicated in autoimmune and inflammatory disorders. However, the molecular mechanism by which the OX40 cosignaling regulates the T‐cell response remains obscure. We found that OX40 associated with a scaffold protein, IQ motif‐containing GTPase‐activating protein 1 (IQGAP1) after ligation by its ligand OX40L. Naïve CD4 + T cells from Iqgap1 −/− mice displayed enhanced proliferation and cytokine secretion upon receiving OX40 cosignaling. A C‐terminal IQGAP1 region was responsible for its association with OX40, and TNFR‐associated factor 2 (TRAF2) bridged these two proteins. The enhanced cytokine response in Iqgap1 −/− T cells was restored by the expression of the C‐terminal IQGAP1. Thus, the IQGAP1 binding limits the OX40 cosignaling. Disease severity of experimental autoimmune encephalomyelitis (EAE) was significantly exacerbated in Iqgap1 −/− mice as compared to wild‐type mice. Additionally, recipient mice with Iqgap1 −/− donor CD4 + T cells exhibited significantly higher EAE scores than those with their wild‐type counterparts, and OX40 blockade led to a significant reduction in the EAE severity. Thus, our study defines an important component of the OX40 cosignaling that restricts inflammation driven by antigen‐activated T cells.Keywords
Funding Information
- Suzuken Memorial Foundation
- SENSHIN Medical Research Foundation
- Daiichi Sankyo Foundation of Life Science
- Japan Society for the Promotion of Science (JP15K19123, JP14J06157, JP24590571, JP15H04640, JP18H02572, JP24390118, JP15H04742)
This publication has 45 references indexed in Scilit:
- Eradication of spontaneous malignancy by local immunotherapyScience Translational Medicine, 2018
- Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing miceProceedings of the National Academy of Sciences, 2016
- OX40, OX40L and Autoimmunity: a Comprehensive ReviewClinical Reviews in Allergy & Immunology, 2015
- Science gone translational: the OX40 agonist storyImmunological Reviews, 2011
- Control of Immunity by the TNFR-Related Molecule OX40 (CD134)Annual Review of Immunology, 2010
- OX40–OX40 Ligand Interaction in T-Cell-Mediated Immunity and Immunopathology2010
- The significance of OX40 and OX40L to T‐cell biology and immune diseaseImmunological Reviews, 2009
- The role of TNF superfamily members in T-cell function and diseasesNature Reviews Immunology, 2009
- Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40Nature Reviews Immunology, 2004
- Co-stimulatory members of the TNFR family: keys to effective T-cell immunity?Nature Reviews Immunology, 2003